Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A clinical trial found that switching HIV meds to long-acting Cabenuva may not require oral lead-in.
A study found no difference in outcomes based on whether participants took oral meds for a month before switching to injectables.
A recent small study examined pairings of antiretrovirals and statins or blood pressure medications.
This is especially the case for people globally who don’t have access to such newer regimens.
Findings suggest exposure to antiretrovirals, including dolutegravir, during pregnancy does not raise the risk of neural tube defects.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Researchers at George Washington University take a look.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
Participants in a study were started on daily oral drugs and then half were switched over to long-acting meds.
This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.
Research in human cells and mice found the antiretroviral suppressed harmful chronic inflammation linked to age-related disorders.
More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
Gilead Sciences has released 96-week results from an ongoing double-blinded study comparing the two regimens.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.